Gianluca Campo

Summary

Affiliation: University of Ferrara
Country: Italy

Publications

  1. doi request reprint Transradial versus transfemoral intervention for acute myocardial infarction: a propensity score-adjusted and -matched analysis from the REAL (REgistro regionale AngiopLastiche dell'Emilia-Romagna) multicenter registry
    Marco Valgimigli
    Institute of Cardiology, University of Ferrara, Ferrara, Italy
    JACC Cardiovasc Interv 5:23-35. 2012
  2. pmc Boosting platelet inhibition in poor responder to aspirin and clopidogrel undergoing percutaneous coronary intervention: role of tirofiban
    Gianluca Campo
    Cardiovascular Institute, Azienda Ospedaliera Universitaria S Anna, Ferrara, Italy
    J Blood Med 1:61-9. 2010
  3. ncbi request reprint Short- versus long-term duration of dual antiplatelet therapy in patients treated for in-stent restenosis: a PRODIGY trial substudy (Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia)
    Gianluca Campo
    Cardiovascular Institute, Azienda Ospedaliero Universitaria Sant Anna, Ferrara, Italy Laboratorio per le Tecnologie delle Terapie Avanzate Center, Ferrara, Italy Electronic address
    J Am Coll Cardiol 63:506-12. 2014
  4. ncbi request reprint Coagulation factors and recurrence of ischemic and bleeding adverse events in patients with acute coronary syndromes
    Gianluca Campo
    Cardiovascular Institute, Azienda Ospedaliero Universitaria S Anna, Ferrara, Italy LTTA Center, Ferrara, Italy Electronic address
    Thromb Res 132:151-7. 2013
  5. pmc Pro-inflammatory genetic profile and familiarity of acute myocardial infarction
    Manuela Ianni
    Department of Experimental Pathology, School of Medicine, University of Bologna, Via S, Giacomo 14, 40126, Bologna, Italy
    Immun Ageing 9:14. 2012
  6. doi request reprint Thrombin generation assay: a new tool to predict and optimize clinical outcome in cardiovascular patients?
    Gianluca Campo
    Cardiovascular Institute, Azienda Ospedaliero Universitaria S Anna, Lumezzane, BS, Italy
    Blood Coagul Fibrinolysis 23:680-7. 2012
  7. ncbi request reprint The in vitro effects of verbascoside on human platelet aggregation
    Gianluca Campo
    Cardiovascular Institute, Azienda Ospedaliero Universitaria S Anna, Ferrara, Italy
    J Thromb Thrombolysis 34:318-25. 2012
  8. doi request reprint Tailored medical and interventional therapy against recurrent stent thrombosis after drug-eluting stenting
    Gianluca Campo
    Cardiovascular Institute, Azienda Ospedaliera Universitaria S Anna, Ferrara, Italy
    Clin Appl Thromb Hemost 16:591-3. 2010
  9. doi request reprint Poor response to clopidogrel: current and future options for its management
    Gianluca Campo
    Cardiovascular Institute, Azienda Ospedaliera Universitaria S Anna, Ferrara, Italy
    J Thromb Thrombolysis 30:319-31. 2010
  10. doi request reprint Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) tr
    Gianluca Campo
    Cardiovascular Institute, AOU S Anna, Ferrara, Italy
    J Am Coll Cardiol 56:1447-55. 2010

Collaborators

Detail Information

Publications39

  1. doi request reprint Transradial versus transfemoral intervention for acute myocardial infarction: a propensity score-adjusted and -matched analysis from the REAL (REgistro regionale AngiopLastiche dell'Emilia-Romagna) multicenter registry
    Marco Valgimigli
    Institute of Cardiology, University of Ferrara, Ferrara, Italy
    JACC Cardiovasc Interv 5:23-35. 2012
    ..This study sought to assess whether transradial intervention, by minimizing access-site bleeding and vascular events, improves outcomes in patients with ST-segment elevation myocardial infarction compared with the transfemoral approach...
  2. pmc Boosting platelet inhibition in poor responder to aspirin and clopidogrel undergoing percutaneous coronary intervention: role of tirofiban
    Gianluca Campo
    Cardiovascular Institute, Azienda Ospedaliera Universitaria S Anna, Ferrara, Italy
    J Blood Med 1:61-9. 2010
    ....
  3. ncbi request reprint Short- versus long-term duration of dual antiplatelet therapy in patients treated for in-stent restenosis: a PRODIGY trial substudy (Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia)
    Gianluca Campo
    Cardiovascular Institute, Azienda Ospedaliero Universitaria Sant Anna, Ferrara, Italy Laboratorio per le Tecnologie delle Terapie Avanzate Center, Ferrara, Italy Electronic address
    J Am Coll Cardiol 63:506-12. 2014
    ....
  4. ncbi request reprint Coagulation factors and recurrence of ischemic and bleeding adverse events in patients with acute coronary syndromes
    Gianluca Campo
    Cardiovascular Institute, Azienda Ospedaliero Universitaria S Anna, Ferrara, Italy LTTA Center, Ferrara, Italy Electronic address
    Thromb Res 132:151-7. 2013
    ..In this review we analyze the current available data and we discuss how this finding may be useful for planning future studies to optimize the treatment of ACS patients. ..
  5. pmc Pro-inflammatory genetic profile and familiarity of acute myocardial infarction
    Manuela Ianni
    Department of Experimental Pathology, School of Medicine, University of Bologna, Via S, Giacomo 14, 40126, Bologna, Italy
    Immun Ageing 9:14. 2012
    ..abstract:..
  6. doi request reprint Thrombin generation assay: a new tool to predict and optimize clinical outcome in cardiovascular patients?
    Gianluca Campo
    Cardiovascular Institute, Azienda Ospedaliero Universitaria S Anna, Lumezzane, BS, Italy
    Blood Coagul Fibrinolysis 23:680-7. 2012
    ..Moreover, a brief summary of its ability to predict ischemic and bleeding risks has been provided...
  7. ncbi request reprint The in vitro effects of verbascoside on human platelet aggregation
    Gianluca Campo
    Cardiovascular Institute, Azienda Ospedaliero Universitaria S Anna, Ferrara, Italy
    J Thromb Thrombolysis 34:318-25. 2012
    ..These preliminary data, while intriguing, require confirmation in subjects receiving verbascoside orally in order to determine whether these findings are clinically relevant...
  8. doi request reprint Tailored medical and interventional therapy against recurrent stent thrombosis after drug-eluting stenting
    Gianluca Campo
    Cardiovascular Institute, Azienda Ospedaliera Universitaria S Anna, Ferrara, Italy
    Clin Appl Thromb Hemost 16:591-3. 2010
    ....
  9. doi request reprint Poor response to clopidogrel: current and future options for its management
    Gianluca Campo
    Cardiovascular Institute, Azienda Ospedaliera Universitaria S Anna, Ferrara, Italy
    J Thromb Thrombolysis 30:319-31. 2010
    ..This paper reviews the impact of clopidogrel poor responsiveness on clinical outcomes, the mechanisms leading to poor effect and the different assays to assess it. Finally, current and future options for its management is discussed...
  10. doi request reprint Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) tr
    Gianluca Campo
    Cardiovascular Institute, AOU S Anna, Ferrara, Italy
    J Am Coll Cardiol 56:1447-55. 2010
    ....
  11. doi request reprint Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome
    Gianluca Campo
    Cardiovascular Institute, Azienda Ospedaliero Universitaria Sant Anna, LTTA Center, Ferrara, Italy
    J Am Coll Cardiol 57:2474-83. 2011
    ..This study sought to investigate the evolving pattern over time of on-clopidogrel platelet reactivity (PR) and its relationship with genotype and clinical outcomes after percutaneous coronary intervention...
  12. doi request reprint Long-term outcome after drug eluting stenting in patients with ST-segment elevation myocardial infarction: data from the REAL registry
    Gianluca Campo
    Unita Operativa di Cardiologia, Azienda Ospedaliera Universitaria S Anna, Ferrara, Italy
    Int J Cardiol 140:154-60. 2010
    ..The purpose of this study was to compare the long-term outcome of STEMI patients undergoing primary PCI with DES vs. bare metal stent (BMS) implantation...
  13. doi request reprint Genetic determinants of on-clopidogrel high platelet reactivity
    Gianluca Campo
    Cardiovascular Institute, Azienda Ospedaliero Universitaria S Anna, Ferrara, Italy
    Platelets 22:399-407. 2011
    ..The aim of this review is to describe the principal gene polymorphisms influencing on-clopidogrel PR and their relationship with long-term clinical outcome...
  14. doi request reprint Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel (3T/2R). Rationale for the study and protocol design
    Marco Valgimigli
    University of Ferrara, Cardiovascular Institute, Arcispedale S Anna Hospital, Corso Giovecca 203, 44100 Ferrara, Italy
    Cardiovasc Drugs Ther 22:313-20. 2008
    ....
  15. doi request reprint Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOppin
    Marco Valgimigli
    Chair of Cardiology, University of Ferrara, Ferrara, Italy
    JACC Cardiovasc Interv 5:268-77. 2012
    ....
  16. doi request reprint Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial
    Marco Valgimigli
    University of Ferrara, Cardiovascular Institute, Arcispedale S Anna Hospital, Ferrara, Italy
    Circulation 125:2015-26. 2012
    ..We evaluated the impact of up to 6 versus 24 months of dual-antiplatelet therapy in a broad all-comers patient population receiving a balanced proportion of Food and Drug Administration-approved drug-eluting or bare-metal stents...
  17. ncbi request reprint Two-year clinical follow-up after sirolimus-eluting versus bare-metal stent implantation assisted by systematic glycoprotein IIb/IIIa Inhibitor Infusion in patients with myocardial infarction: results from the STRATEGY study
    Marco Valgimigli
    Institute of Cardiology, University of Ferrara, Ferrara, Italy
    J Am Coll Cardiol 50:138-45. 2007
    ..Moreover, the distribution of clinical events in relation to thienopyridine discontinuation was thoroughly investigated...
  18. doi request reprint Persistent coronary no flow after wire insertion is an early and readily available mortality risk factor despite successful mechanical intervention in acute myocardial infarction: a pooled analysis from the STRATEGY (Single High-Dose Bolus Tirofiban and S
    Marco Valgimigli
    Cardiovascular Institute, University of Ferrara, Ferrara, Italy
    JACC Cardiovasc Interv 4:51-62. 2011
    ..These studies sought to investigate the impact on mortality of coronary flow after passage of the wire through the culprit vessel in patients with ST-segment elevation myocardial infarction (STEMI) undergoing mechanical reperfusion...
  19. doi request reprint Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
    Marco Valgimigli
    Cardiovascular Institute, University of Ferrara, S Anna Hospital, Corso Giovecca 203, Ferrara, Italy
    Circulation 119:3215-22. 2009
    ..Whether this reflects suboptimal platelet inhibition per se, which might benefit from more potent antiplatelet agents such as tirofiban, is unknown...
  20. doi request reprint Three-year follow-up of the MULTIcentre evaluation of Single high-dose Bolus TiRofiban versus Abciximab with Sirolimus-eluting STEnt or Bare-Metal Stent in Acute Myocardial Infarction StudY (MULTISTRATEGY)
    Marco Valgimigli
    Cardiovascular Institute, University of Ferrara, Italy
    Int J Cardiol 165:134-41. 2013
    ..5% in the BMS and 7.8% in the SES groups (P = 0.0039), reflecting a reduction of reintervention rates (10.2% vs. 3.2%). A three-year follow-up was performed to extend previous short- to mid-term findings...
  21. doi request reprint Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial
    Marco Valgimigli
    Cardiovascular Institute, University of Ferrara, Ferrara, Italy
    JAMA 299:1788-99. 2008
    ..Similarly, the use of drug-eluting stents in this patient population is currently discouraged because of conflicting results on efficacy reported in randomized trials and safety concerns reported by registries...
  22. ncbi request reprint Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: insights into the STRATEGY Study
    Gianluca Campo
    Department of Cardiology, University of Ferrara, Ferrara, Italy
    J Am Coll Cardiol 48:2178-85. 2006
    ....
  23. ncbi request reprint Poor responsiveness to clopidogrel: drug-specific or class-effect mechanism? Evidence from a clopidogrel-to-ticlopidine crossover study
    Gianluca Campo
    Cardiovascular Institute, Azienda Ospedaliera Universitaria S Anna, Ferrara, Italy
    J Am Coll Cardiol 50:1132-7. 2007
    ....
  24. ncbi request reprint Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial
    Marco Valgimigli
    Chair of Cardiology, University of Ferrara, Cardiovascular Institute, Arcispedale S Anna, Italy
    JAMA 293:2109-17. 2005
    ..At current European list prices, the use of tirofiban instead of abciximab would absorb the difference in cost between stenting with sirolimus-eluting vs bare-metal stents...
  25. ncbi request reprint A strategy to offset the extra cost of sirolimus-eluting stent in patients undergoing intervention for acute myocardial infarction
    Marco Valgimigli
    Cardiovascular Institute, University of Ferrara, Ferrara, Italy
    Int J Cardiol 128:53-61. 2008
    ....
  26. ncbi request reprint Two-by-two factorial comparison of high-bolus-dose tirofiban followed by standard infusion versus abciximab and sirolimus-eluting versus bare-metal stent implantation in patients with acute myocardial infarction: design and rationale for the MULTI-STRATEG
    Marco Valgimigli
    Cardiology, University of Ferrara, Ferrara, Italy
    Am Heart J 154:39-45. 2007
    ..Similarly, whether tirofiban administered at high-bolus dose (HBD) followed by standard infusion is a valuable alternative to abciximab in the setting of ST-segment elevation myocardial infarction remains uncertain...
  27. doi request reprint Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention Design and rationale for the PROlonging Dual-antiplatelet treatment
    Marco Valgimigli
    Cardiology Department, University of Ferrara, Ferrara, Italy
    Am Heart J 160:804-11. 2010
    ....
  28. ncbi request reprint High-dose bolus tirofiban and sirolimus eluting stent versus abiciximab and bare metal stent in acute myocardial infarction (STRATEGY) study--protocol design and demography of the first 100 patients
    Marco Valgimigli
    University of Ferrara, Cardiovascular Institute, Arcispedale S Anna Hospital, C rso Giovecca 203, 44100 Ferrara, Italy
    Cardiovasc Drugs Ther 18:225-30. 2004
    ..With current European list prices, the use of tirofiban instead of abciximab would save enough money to absorb the difference between SES and BMS...
  29. doi request reprint Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials
    Marco Valgimigli
    Cardiovascular Institute, Azienda Opedaliera Universitaria di Ferrara, Corso Giovecca 203, Ferrara 44100, Italy
    Eur Heart J 31:35-49. 2010
    ..To perform a thorough and updated systematic review of randomized clinical trials comparing tirofiban vs. placebo or vs. abciximab...
  30. ncbi request reprint Latest clinical data on testing for high on-treatment platelet reactivity
    Luca Fileti
    Cardiovascular Institute, Azienda Ospedaliero Universitaria Sant Anna, Ferrara, Italy
    Rev Cardiovasc Med 12:S14-22. 2011
    ....
  31. doi request reprint Different clinical models of CD34 + cells mobilization in patients with cardiovascular disease
    Elisa Cangiano
    U O Cardiologia, Cardiovascular Institute, Azienda Ospedaliero Universitaria S Anna, Ferrara, Italy
    J Thromb Thrombolysis 32:1-8. 2011
    ..Myocardial necrosis with simultaneous elevation of VEGF and SDF-1α causes a significant CD34 + cells mobilization in patients with cardiovascular disease...
  32. doi request reprint On-treatment platelet reactivity in patients with chronic obstructive pulmonary disease undergoing percutaneous coronary intervention
    Gianluca Campo
    Department of Medical Sciences, Cardiovascular Institute, Azienda Ospedaliero Universitaria S Anna, Cona, Ferrara, Italy
    Thorax 69:80-1. 2014
    ..Those with concomitant COPD showed higher on-treatment PR values both at the time of PCI and 1 month after. This finding may contribute to explain the poor prognosis of COPD patients after MI and PCI. ..
  33. ncbi request reprint [Current options to manage clopidogrel poor responsiveness]
    Luca Fileti
    U O di Cardiologia, Azienda Ospedaliera Universitaria S Anna, Ferrara
    G Ital Cardiol (Rome) 11:881-9. 2010
    ..Finally, current and future options for its management are discussed...
  34. pmc Factor XIIIA-V34L and factor XIIIB-H95R gene variants: effects on survival in myocardial infarction patients
    Donato Gemmati
    Center Study Haemostasis and Thrombosis, Department of Biomedical Sciences and Advanced Therapies, University of Ferrara, Ferrara, Italy
    Mol Med 13:112-20. 2007
    ..Genetically determined higher FXIII activity might influence post-MI outcome. This paves the way for using FXIII molecules to improve myocardial healing, recovery of functions, and survival after infarction...
  35. pmc Abciximab: a reappraisal of its use in coronary care
    Marco Valgimigli
    Cardiovascular Institute, Azienda Ospedaliera Universitaria S Anna, Ferrara, Italy and Cardiovascular Research Centre, Salvatore Maugeri Foundation, IRCCS Gussago BS, Italy
    Biologics 2:29-39. 2008
    ..Finally, abciximab has been also used in abciximab-coated stent, with only bolus administration regimen and for direct intracoronary use with promising results that may extend and/or modify its current use in clinical practice in future...
  36. doi request reprint ACE inhibition modulates endothelial apoptosis and renewal via endothelial progenitor cells in patients with acute coronary syndromes
    Elisa Cangiano
    Department of Cardiology, University of Ferrara, Ferrara, Italy
    Am J Cardiovasc Drugs 11:189-98. 2011
    ....
  37. pmc In vitro characterization of circulating endothelial progenitor cells isolated from patients with acute coronary syndrome
    Diana Campioni
    Department of Medical Sciences, Section of Hematology, Azienda Ospedaliero Universitaria, Arcispedale Sant Anna, University of Ferrara, Ferrara, Italy
    PLoS ONE 8:e56377. 2013
    ....
  38. ncbi request reprint Percutaneous treatment of multivessel coronary disease in the drug eluting stent era: comparison of bare-metal stents, drug-eluting stents and a mixed approach in a large multicentre registry
    Elisabetta Varani
    Unita Operativa di Cardiologia, Ospedale S Maria delle Croci, Ravenna, Italy
    EuroIntervention 2:474-80. 2007
    ..However, this selective use of DES was independently associated with a lower incidence of 1-year TVR and MACE. Whether increasing the rate of DES utilisation would further improve the clinical outcome remains to be investigated...
  39. ncbi request reprint Safety and long-term efficacy of sirolimus eluting stent in ST-elevation acute myocardial infarction: the REAL (Registro REgionale AngiopLastiche Emilia-Romagna) registry
    Gianfranco Percoco
    Unità di Cardiologia, Universita di Ferrara, Ospedale S Anna Ferrara, Ferrara
    Cardiovasc Drugs Ther 20:63-8. 2006
    ..Limited data are available for sirolimus eluting stent (SES) implantation in patients with ST-segment elevation myocardial infarction (STEMI)...